Background
There is growing evidence around the benefits of early ART initiation both in terms of health outcomes and TasP.

TasP is especially relevant in seroconverters who have very high viral loads [1].

Aim
To assess our management of seroconverting patients.

Methods

Conclusion
There were significant improvements in 6 month CD4 count in those who started ART immediately compared with delayed starters.

This combined with the reduced time to virological suppression and fulfilment of U=U reflect the wide reaching benefits of early ART.

References

Abbreviations
ART, antiretroviral therapy; TasP, treatment as prevention; U=U, undetectable=untransmissible.